Breathe Well Live Well
|
Sweden says AstraZeneca used questionable asthma drug API from Indian plant
FiercePharma Manufacturing AstraZeneca ($AZN) said last week it was closing a plant in India that made the API for asthma drugs, noting there is not much demand any longer for the terbutaline sulfate it makes. But what the U.K. company did not say was that before its closing … |
View full post on asthma – Google News
|
FDA cites Cipla India plant after U.S. recall of asthma drug
FiercePharma Manufacturing In May, India's Cipla voluntarily pulled a lot of its levalbuterol from the U.S. market after the asthma inhalation drug failed a test for a degradant. Shortly after, FDA inspectors visited the plant in Indore where Cipla made the product and came away … |
View full post on asthma – Google News
|
New Manufacturing Method Improves Drug Delivery of Asthma Inhalers
Pharmaceutical Technology Magazine (blog) A chemical engineering team from Monash University in Australia developed a method to manufacture ultrafine particles that will improve the consistency and efficiency of drugs used in metered-dose inhalers to treat asthma, the University announced in a … |
View full post on asthma – Google News
|
Glenmark's Singulair generic recalled for fishy smell
FiercePharma Manufacturing It has happened again, and this time, it involves nearly 600,000 bottles of Glenmark Pharmaceuticals' generic version of the Merck ($MRK) blockbuster asthma med, Singulair. The company is voluntarily recalling 29 lots of its montelukast sodium tablets. |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News